ClinicalTrials.gg
CompletedNCT00137410Updated Jun 10, 2008

Celebrex Short Versus Long Therapy In Osteoarthritis Of The Knee

A Phase 3 interventional study of Celebrex in Osteoarthritis,Knee, sponsored by Pfizer. Completed at 16 sites in Italy. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2008-06-10.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 14 studies testing celecoxib in Osteoarthritis, Knee — 1 open to participants now, 1 under way, none of them phase 3. Celecoxib · Osteoarthritis, Knee.

Enrollment
8th of 14
200 · median 216
Started
2002
with 1 other
Phase 3
2 of 14
none open now
Registered
1st of 14
by date
Lead sponsor
1 of 14
Pfizer

Among the 14 studies testing celecoxib in Osteoarthritis, Knee, this one is the 8th largest by enrollment, is one of 2 that started in 2002, is one of 2 in phase 3, and was the 1st registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 624 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

1 of the 14 studies testing celecoxib in Osteoarthritis, Knee is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About celecoxib

Celecoxib: first FDA approval 1998 (CELEBREX), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 385 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 114 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing celecoxib in Osteoarthritis, Knee, or all of them as a file.
02

Study summary

This is a phase III, multicentre, randomized, double blind, parallel-group, pilot study designed to compare a long term (12 weeks) versus a short term (2 weeks) treatment with celecoxib 200 mg/die in treatment and prevention of new flare in patients with osteoarthritis of the knee.

03

Conditions studied

  • Osteoarthritis,Knee
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnosis of OA of the knee according to the ACR Classification Criteria for osteoarthritis;
  • patients in flare

Exclusion criteria

Exclusion Criteria:

  • any concomitant inflammatory rheumatic condition which may interfere with the assessment of OA
  • clinical or radiological evidence of chondrocalcinosis
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
200 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Time elapsing between the last drug administration and a new flare, if any, occurring within a 12 months FU and proportion pts with a new flare

Secondary outcomes

  1. Flare intensity WOMAC OA index Psycho-affective Index Pt's assessment of OA pain (VAS) Pt's & Physician's global assessment disease severity Incidence of total AEs Incidence of GI AEs: Incidence of changes in: hematology, renal function, liver function

07

Study locations

16 sites
  • Pfizer Investigational Site
    Rutigliano, BA 70018, Italy
  • Pfizer Investigational Site
    Arenzano (GE), 16011, Italy
  • Pfizer Investigational Site
    Cagliari - Monserrato, Italy
  • Pfizer Investigational Site
    Foggia, 71100, Italy
  • Pfizer Investigational Site
    Genova, 16100, Italy
  • Pfizer Investigational Site
    Genova, 16132, Italy
  • Pfizer Investigational Site
    Jesi ( AN), 60035, Italy
  • Pfizer Investigational Site
    Milano, 20122, Italy
  • Pfizer Investigational Site
    Milano, 20157, Italy
  • Pfizer Investigational Site
    Padova, 35100, Italy
  • Pfizer Investigational Site
    Palermo, 90146, Italy
  • Pfizer Investigational Site
    Pavia, 27100, Italy
  • Pfizer Investigational Site
    Potenza, 85100, Italy
  • Pfizer Investigational Site
    Roma, 00149, Italy
  • Pfizer Investigational Site
    Siena, 53100, Italy
  • Pfizer Investigational Site
    Venezia, 30122, Italy
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2002, a primary completion of Mar 2006 and a completion of Mar 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2005
First posted
Aug 29, 2005
Start
Nov 2002
Primary completionActual
Mar 2006
CompletionActual
Mar 2006
Last update
Jun 10, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00137410
Lead sponsor
Pfizer
First posted
Aug 29, 2005
Start date
Nov 2002
Primary completion
Mar 2006
Completion
Mar 2006
Last update
Jun 10, 2008

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2006. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Celecoxib

Start the discussion